United States Uterine Fibroids Treatment Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The united states uterine fibroids treatment devices market size is projected to expand from USD 1.71 billion in 2025 and USD 1.82 billion in 2026 to USD 2.55 billion by 2031, registering a CAGR of 6.95% between 2026 to 2031. This report is Segmented by Technology (Surgical, Laparoscopic, Ablation, and Embolization Techniques), Mode of Treatment (Invasive Treatment, Minimally Invasive Treatment, Non-Invasive Treatment), and End User (Hospitals, Ambulatory Surgical Centers, Office-Based Gynecology Clinics, Interventional Radiology Centers). The Market Forecasts are Provided in Terms of Value (USD).

United States Uterine Fibroids Treatment Devices Market Trends and Insights

Uterus-Preserving Treatment Preference

Patient preference for uterus-sparing care has changed referral behavior across the United States uterine fibroids treatment devices market, especially in health systems that now offer multiple procedural alternatives before hysterectomy is considered. A 2025 JAMA Network Open study showed that hysterectomy still represented 73.4% of fibroid treatment encounters, while UFE accounted for only 3.5%, which shows how much room remains for device-led treatment substitution. This demand pattern is stronger among reproductive-age women who want symptom control without losing the uterus, and it matters even more in populations where fibroids appear earlier and with greater severity. In the United States uterine fibroids treatment devices market, that preference does not benefit only one modality because it lifts interest in RFA, embolization, and focused ultrasound at the same time. The result is a broader expansion path for manufacturers that can fit different patient profiles and care settings inside the same treatment journey.

Payer Expansion for Lap-RFA

Reimbursement has been one of the main commercial barriers for laparoscopic radiofrequency ablation, so payer coverage gains are now one of the most immediate growth supports for the United States uterine fibroids treatment devices market. Medica’s published policy covers laparoscopic RFA for uterine fibroids, and ACOG Practice Bulletin 228 continues to support the procedure in the clinical decision framework used by providers and payers. As coverage improves, more cases can move into ASC and office-based settings, which lowers system friction for ablation adoption and broadens the commercial reach of the United States uterine fibroids treatment devices market. This shift also favors manufacturers that built compact or single-use tools rather than relying only on large installed-capital systems. CMS fee schedule rules and local coverage processes continue to shape procedure economics, so reimbursement execution remains central to near-term adoption even when clinical support is already in place.

Uneven Reimbursement for MRgFUS

MRgFUS remains clinically relevant in the United States uterine fibroids treatment devices market, but commercial uptake is still limited because payers continue to classify the relevant CPT codes as investigational. Cigna, Blue Shield policies, and similar payer positions keep most volumes concentrated in academic centers where alternative funding or research pathways are more realistic. That gap between FDA approval and broad reimbursement slows market conversion even when the clinical value proposition is clear. In the United States uterine fibroids treatment devices market, this means non-invasive platforms have not translated their technology profile into wide commercial volume. Until a stronger cost-effectiveness case is accepted at scale, MRgFUS will likely remain more important in select centers than in broad routine care.

Other drivers and restraints analyzed in the detailed report include:

• Shift To Office and ASC Hysteroscopy Workflows
• Hologic Portfolio Expansion After Sonata Integration
• Fertility And Pregnancy Evidence Gaps

Segment Analysis

Surgical techniques held 31.23% of the United States uterine fibroids treatment devices market share in 2025, which kept surgery as the largest technology category by revenue. That position remained supported by hysterectomy and myomectomy, which continue to offer definitive symptom resolution and strong institutional familiarity. A 2025 JAMA Network Open analysis found that hysterectomy represented 73.4% of fibroid treatment encounters nationally, which shows why surgical volume still anchors the technology mix. Broad insurance coverage and well-established hospital workflows also helped preserve surgical relevance across the United States uterine fibroids treatment devices market. Laparoscopic Techniques stayed between surgery and ablation in the adoption curve, with robotic-assisted myomectomy gaining ground as da Vinci access expands across outpatient sites.

The United States uterine fibroids treatment devices market size for ablation techniques is projected to grow at a 7.41% CAGR through 2031, making it the fastest-growing technology group. This growth reflects Hologic’s dual-platform RFA position after the Gynesonics integration and rising physician comfort with transcervical and laparoscopic workflows. The Sonata pivotal study reported a 2.2-day median return to normal activity, which aligns with patient preference for lower-disruption treatment paths. MRgFUS and USgHIFU remain part of the ablation opportunity, but reimbursement limits still restrict their contribution to the United States uterine fibroids treatment devices market. Embolization Techniques remain clinically established, and Merit’s Embosphere data continue to support strong physician loyalty in a consumable-driven part of the portfolio mix.

Complete Report Scope:

• By Technology
  • Surgical Techniques
    • Hysterectomy
    • Myomectomy
  • Laparoscopic Techniques
    • Laparoscopic Myomectomy
    • Myolysis
  • Ablation Techniques
    • Laparoscopic Radiofrequency Ablation
    • Transcervical Radiofrequency Ablation
    • MRI-guided Focused Ultrasound
    • Ultrasound-guided High-intensity Focused Ultrasound
  • Embolization Techniques
    • Uterine Fibroid Embolization
    • Embolic Microspheres
    • PVA Particles
• By Mode of Treatment
  • Invasive Treatment
    • Open Surgery
    • Robotic-assisted Surgery
  • Minimally Invasive Treatment
    • Laparoscopic Procedures
    • Hysteroscopic Procedures
    • Uterine Artery Embolization
  • Non-invasive Treatment
    • MR-guided Focused Ultrasound
    • Ultrasound-guided High-intensity Focused Ultrasound
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Office-based Gynecology Clinics
  • Interventional Radiology Centers

List of Companies Covered in this Report:

• Axora Medical, Inc.
• Boston Scientific
• Conmed
• Cook Group
• The Cooper Companies
• GE HealthCare Technologies Inc.
• Hologic
• INSIGHTEC Ltd.
• Intuitive Surgical, Inc.
• Johnson & Johnson MedTech
• Karl Storz
• Medtronic
• Merit Medical Systems
• Minerva Surgical
• Olympus
• Profound Medical
• Richard Wolf
• Siemens Healthineers
• Stryker
• Terumo

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support